Exagen Inc. Reports Strong Q3 2025 Results

Autoimmune Diagnostics Exagen provides diagnostic testing for autoimmune and rheumatic diseases. Its tests are designed to help clinicians resolve diagnostically complex cases and support ongoing disease management. AVISE CTD AVISE CTD is the company's flagship testing service for lupus and other connective-tissue diseases. It combines...

Recent company news

XGNExagen2026-08-04 12:00 EST

Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus

XGNExagen2026-05-11 12:00 EST

Exagen Inc. Reports First Quarter 2026 Results

Stock data

Close: 7.92 USD
Market cap: 116.45M USD
Exchange: NASDAQ
Sector: MedTech
Location: United States

Exagen Inc. Reports Strong Q3 2025 Results

Related news

Exagen Inc. Reports Second Quarter 2026 Financial Results

Exagen to Announce Second Quarter Financial Results on August 4, 2026

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

SERA PROGNOSTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Exagen